FDA issues complete response letter for roflumilast NDA

May 18 2010NewsGuard 100/100 Score

Forest Laboratories, Inc. (NYSE: FRX) and Nycomed today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast. Roflumilast was reviewed as a potential treatment to reduce COPD exacerbations associated with chronic bronchitis in patients at risk for exacerbations.

In the complete response letter the FDA requested certain additional information and analyses. No additional patient trials have been requested for the continued review of the NDA. Forest and Nycomed are committed to working with the FDA to address the outstanding matters and the companies anticipate a response to the FDA during the third calendar quarter of 2010.

SOURCE Nycomed and Forest Laboratories

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Ultra-processed foods dominate children's diets from toddlerhood to middle childhood
Updated Food Compass 2.0 improves food health ratings using new diet data
Limiting fast-food outlets can reduce childhood overweight and obesity
Ultra-processed food linked to weight gain and lower well-being in adolescents
Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group
High levels of microplastics found in prostate tumors, possibly linked to take-out food
Key triggers for food allergies in children after organ transplants
Frequent ultra-processed food consumption raises mortality risks, especially in women

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty